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Torkel Richert† and Björn Johnson*†Abstract
Background: Illicit use of methadone and buprenorphine has been described as a growing problem in Sweden in
recent years, and has been associated with an increased drug-related mortality. Critics claim that the substances
have become popular among adolescents and that they function as a gateway to heroin use. The aim of this study
is to investigate, firstly, the extent to which illicit use of methadone and buprenorphine occurs among adolescents
and young adults in Sweden, and secondly, at what stage in a user’s drug career these substances tend to appear.
Methods: The study is based on surveys and structured interviews on drug use among various populations of
young people, in addition to qualitative interviews with 86 informants who, in their professional capacity, encounter
adolescents or young adults who are using illicit drugs.
Results: Illicit use of methadone and buprenorphine is rare among young people in Sweden. According to high
school surveys, less than 0.1% have tried these substances. Among young drug users in general, few have tried the
substances, and there is nothing to indicate that they act as gateway drugs. Among adolescents and young adults
with severe drug problems, however, the illicit use of methadone and buprenorphine is more common (54% in a
compulsory care sample). These substances normally enter the drug career late, and few use them as their main
drug of choice. Other prescription drugs, like benzodiazepines and tramadol, are used by adolescents to a far
greater extent. Diversion and illicit use of methadone and buprenorphine is not seen as a serious problem by the
professionals interviewed. A general view is that the substances are mainly used by people with a heroin or
polydrug addiction, often for “self-medication” purposes. However, several informants express concern that
methadone and buprenorphine may cause fatalities among young drug users without an opioid tolerance.
Conclusions: Illicit use of methadone and buprenorphine among young drug users is not a widespread problem in
Sweden. Harm-reduction measures should target drug users with more severe problems, among whom illicit use of
methadone and buprenorphine is more common and pose a medical risk. Illicit use of other prescription drugs,
which are less controlled and more widely used by young people, is an important issue for further research.
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Methadone and buprenorphine are secure and effective
pharmaceutical drugs when used for opioid substitution
treatment (OST) [1-3]. However, if the substances are used
in a non-medical fashion, they can cause serious problems.
Methadone is highly toxic, and may be lethal for anyone
who has not developed a sufficient opiate/opioid tolerance
[4,5]. Buprenorphine is less potent, but if mixed with
alcohol or sedatives there is still a great risk of polydrug* Correspondence: bjorn.johnson@mah.se
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article, unless otherwise stated.intoxication [6,7]. Both substances are highly addictive,
and attractive on the illicit drug market [8,9].
In recent years, as OST has expanded in Sweden,
attention has been drawn to illicit use of methadone and
buprenorphine as a growing problem. aThe number of
deaths related to methadone and buprenorphine have
increased substantially, and in 2010 they exceeded
heroin-related deaths for the first time [10]. Diversion
from treatment programs has been suggested as a plausible
explanation [11]. Moreover, critical voices in the debate
have contended that the substances have become popular
among and widely used by adolescents, that there is a riskCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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addicted to the substances, and that they provide gateway
drugs to heroin use [12].
Among other things, the debate has led to a questioning
of the legitimacy of OST, stricter controls in some
treatment programs, and the withdrawal of the
buprenorphine-based prescription drug Subutex from
the market. This decision was taken without any
existing research into the phenomenon. No research
has been conducted regarding the extent to which
methadone and buprenorphine are being diverted
from the Swedish OST programs, the structure of the
illicit market for these substances, or to what extent
the substances come into the hands of young people
without a drug addiction. A couple of Swedish studies
of the illicit use of buprenorphine have been conducted
[13,14]. Both focus exclusively on injecting drug users
(IDUs), and indicate that, within this community, such use
is very common. The most common reason for using the
substance outside the treatment system was to alleviate
heroin withdrawal symptoms, in addition to performing
self-detoxification or managing opioid substitution on
your own.
Whether diversion and illicit use of methadone and
buprenorphine should be seen as a serious problem or
not, depends not only on the extent of these phenomena,
but also on the issue of which populations are using the
substances and for what purpose. If these substances are
mainly used by opioid IDUs for self-medication purposes,
this may be seen as a less serious problem than if the
substances to a great extent are used by adolescents
and young adults early on in their drug careers.
The aim of this study is to investigate, firstly, the extent
to which illicit use of methadone and buprenorphine
occurs among adolescents and young adults in Sweden,
and secondly, at what stage in a user’s drug career these
substances tend to appear. In addition, we also investigate
the extent to which diversion and illicit use of substances
from the treatment programs is perceived as a serious
problem by professionals who, in their line of work,
encounter young people who use drugs.
There is a growing body of international research into
illicit use of methadone and buprenorphine. However,
this research has mainly focused on IDUs, or users
admitted to OST programs. The first studies into illicit
use of methadone were conducted in the US in the mid
1970s, some years after the rapid expansion of methadone
clinics throughout the country. Ethnographic field studies
from the middle of that decade paint a picture of
how methadone had been integrated into the drug
user environment and the street culture, and how it
had become a prominent street drug [15,16]. More
recent studies indicate that illicit methadone use is
very common among opiate users—mainly among olderdrug users, users who have previously undergone OST, and
people who recently have completed detoxification [17].
The lifetime prevalence of illicit methadone use among
opiate users outside treatment has varied between 17% and
73% in different studies [17-20], but a high prevalence is
the rule rather than the exception.
Diversion and illicit use of buprenorphine is the subject
of a recently published research review [9]. The review
shows that buprenorphine, like methadone, is a commonly
used substance among IDUs and people with a heroin
addiction in a great number of countries all over the world.
Two countries, Finland and France, stand out in this
context. A study from Finland shows that buprenorphine is
the most commonly used opiate/opioid, and that 97% of
the people applying for OST have buprenorphine as
their main drug [21]. Studies from France indicate that a
majority of IDUs either inject only buprenorphine, or are
using the drug as part of a polydrug addiction, primarily
in conjunction with heroin or cocaine [22,23].
Internationally there is also a dearth of knowledge as
regards the extent to which methadone and buprenorphine
are used by adolescents or young adults. An Irish study
which investigated the journey into injecting drug use
among a cohort of 104 young adults in OST showed that
only 3% were introduced to opioid dependence via
methadone (96% were introduced via heroin) [24]. A
couple of studies indicate that, for some individuals,
buprenorphine may play a major role in their drug
career. In a survey study of intravenous drug users in the
country of Georgia [25], 11.5% claimed that buprenorphine
was the first drug to which they developed an addiction. An
Indian study show that when transitioning to intravenous
drug use, users tend to prefer buprenorphine instead of
heroin [26]. However, these studies too are based on adults
with severe drug problems.
Methods
In order to investigate the extent of the illicit use of
methadone and buprenorphine among various groups of
adolescents and young adults in Sweden, we have
collected data covering three populations: (1) a general
population of high school students, (2) adolescents who
use illegal drugs, and (3) adolescents and young adults
with severe drug problems (many of them would classify
at the severe end of the substance use disorder spectrum).
By including populations with different experiences of
drug use, we hope to get a picture of how common
these substances are in comparison to other drugs,
and at what stage in a user’s drug career they tend to
be introduced.
We have compiled qualitative as well as quantitative
data material about the three populations. By using
different types of data—data triangulation—we are
hoping to provide a comprehensive view of the
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summarized in Table 1.
Quantitative data
Our quantitative data is gathered from three data sets
which we have been given access to via the organizations
and authorities that assemble them. As substances,
methadone and buprenorphine are only infrequently
separately specified in official statistics or reports on
drug use, and as a consequence we have chosen to use
unpublished raw data. We use the following databases:
1. National data on drug use among Swedish high school
students 2007–2012, taken from the annual self-report
surveys on drug use conducted by CAN
(Centralförbundet för alkohol- och
narkotikaupplysning—The Swedish Council for
Information on Alcohol and Other Drugs), a non-
governmental organization conducting nationwide
anonymous surveys (on the government’s behalf) at a
representative selection of Swedish schools. Each year
some 4,000 pupils in year 9 (aged 15) of compulsory
school, and some 4,000 second-year high school
students take part. We are using the high school data
set only (17 to 18 years of age).
2. Regional data on young drug users in outpatient
care 2010–2012, taken from the UngDOK database.
UngDOK is a documentation system used in
outpatient care of young people (13 to 25 years of
age) with varying levels of drug problems. The
system is based on structured interviews with the
clients. Data are reported from outpatient clinics in
Sweden’s three major cities—Stockholm,
Gothenburg, and Malmö—as well as a few minor
towns [27].
3. National data on adult drug users (18 to 29 years of
age) in compulsory treatment 2002–2012, taken
from the SiS research registry. SiS (Statens
institutionsstyrelse—The National Board of
Institutional Care) is a national authority in charge
of compulsory treatment and treatment of
adolescents with severe drug problems and/or
psychosocial problems, and of adults with a
life-thretening addiction. SiS is running a largeTable 1 Summary of populations and data sets
Quantitative data
General population of high
school students
Survey data on drug use among
Swedish high school students (CAN)
Young drug users Structured interview data from outpatient
drug treatment units (UngDOK)
Adolescents and young adults
with severe drug problems
Structured interview data from
compulsory care units (SiS)number of institutions all over the country. The
authority uses the ADAD (Adolescent Drug Abuse
Diagnosis) [28] and DOK [29] documentation systems.
All data are gathered in a central research registry.
The analysis of the data, in the form of calculation of
frequencies and averages, was conducted in SPSS.
Qualitative data
Our qualitative data material is made up of semi-
structured interviews with professionals who, in their
line of work, come into contact with young people with
varying degrees of drug use. We have conducted a total
of 86 interviews in five Swedish cities; two big cities
(Gothenburg and Malmö) and three mid-size towns
(Lund, Norrköping and Jönköping). The locations were
selected in order to cover a variety of local drug scenes.
In bigger cities with many units working with the same
populations, we spoke to coordinators and a few
randomly selected professionals. The greater part of the
interviews took place in the first half of 2012 with some
supplementary interviews in the Spring of 2013. The
material is summarized in Table 2 below.
The majority of the interviews took place over the
telephone, although a number were also conducted
face-to-face or via e-mail. The informants were, among
other things, asked about their working methods, the
target populations they encounter as well as which
narcotic substances or classified prescription drugs
are the most common among these target populations.
Following on from this, we asked more specific questions
about methadone or buprenorphine: whether these sub-
stances were used by the adolescents and young adults that
the informants come into contact with, whether they could
see any change or trend over time, and finally, their own
views on diversion and illicit use.
The more extensive interviews were digitally recorded
and transcribed verbatim. The analysis was performed as
a manual, three-step qualitative textual analysis. First, we
made a close reading of the material, and performed a
summary coding based on the overarching themes in the
interview guide. Then we made a second, more detailed,
coding, where we identified various patterns—similarities
and differences—in relation to the original. Finally, weQualitative data
Interviews with high school counselors
Interviews with police officers (adolescent units and drug squads),
outreach/social street workers, youth workers, social workers within
the police force, outpatient drug treatment staff, NGO-representatives
Interviews with addiction treatment staff (detox units, institutional
care, compulsory care) and police officers (drug squads)
Table 2 Interviews at differens locations
Gothenburg Malmö Lund Norrköping Jönköping Total
Police (adolescent units and drug squads) 5 3 1 2 2 13
School counselors (high school) 5 4 2 1 4 16
Outreach/social street workers, youth workers, social workers in the police force 2 6 2 2 5 17
Addiction treatment staff (outpatient care, institutional/compulsory care, detox units) 15 10 4 4 1 34
Representatives of associations and NGOs 2 3 1 6
Total 29 26 9 10 12 86
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identify suitable illustrative and representative quotes.
Ethical considerations
The study forms part of a larger research project on
diversion and illicit use of methadone and buprenorphine
in Sweden, financed by the Swedish Council for Working
Life and Social Research. bThe project is conducted
in accordance with the Swedish Ethical Review Act
(SFS 2004:460), and has been reviewed and authorized
by the Regional Ethical Review Board at Lund University
(dnr 2011/763).
The quantitative data used for this sub-study were
de-identified. The CAN drug habit survey was
performed anonymously, and as far as the UngDOK
and SiS databases are concerned, we have only had
access to information about gender, age and drug
experiences of the clients.
The interviewees in the qualitative parts of the study
have been informed about the study and its aims, as well
as their right to end their participation at any time. In
the article, their quotes have been anonymized.
Results
High school students—few are aware of methadone and
buprenorphine, and extremely few have tried the
substances
Data from CAN’s high school survey of 2012 show that
some 20% of boys and 15% of girls in the second year
(17–18 years) stated that they had tried narcotics at
some point. The most common substance by far for both
sexes was cannabis (in total approx. 16%), followed by
benzodiazepines (some 2%) amphetamine, ecstasy and
cocaine (approx. 1% each), LSD (0.5%) and heroin (0.3%).
Methadone and buprenorphine are not specified in the
CAN surveys, but the surveys do include open-ended
questions where the respondents can enter any other
narcotic substances they have used, including any
prescription drugs they have used in combination
with alcohol for intoxication purposes. Between 2007
and 2012, a total of 26,848 high school students answered
the questionnaire on drug use. Other narcotic substances
have together totaled approx. 1% each year, and each yearsomewhere between 5% and 8% of the respondents
have claimed that they have used some form of pre-
scription drug together with alcohol in order to
increase intoxication [30]. During the entire 2007–2012
period, only four high school students stated that they had
used buprenorphine. Methadone does not appear even
once in these data. As a notable comparison, during the
same period 53 students said they had used tramadol
(a mild opioid analgesic).
Interviews with counselors at high schools in the five
locations investigated indicate similar results. Very few
high school students are caught in possession of, or test
positive for narcotics. cIn a large majority of cases where
young people have tested positive for narcotics, or have
admitted to drug use, the substance has been cannabis. In
recent years a small number of cases of cocaine, amphet-
amine, and benzodiazepine use have been detected.
None of the counselors interviewed have personally come
across any confirmed cases of methadone or buprenorphine
use, nor have they heard of any colleagues who have done
so. The following quote is representative of our school
counselor interviews:
Over the years, cannabis has been the most common
[classified] drug by far, it is almost exclusively a case
of cannabis. Only a small number test positive for
other substances. Having said that, tramadol has
increased in recent years—it seems to get more and
more common. We have never seen methadone or
buprenorphine din the drugs tests, and I personally
have never come across them during all my time as a
high school counselor. I doubt that more than a
handful of high school students are even aware of
these substances. (School Counselor Co-ordinator for
Malmö’s municipal high schools)
Tramadol is mentioned in this quote. This is the pre-
scription drug most often mentioned in the interviews.
A number of other counselors confirm that tramadol
have become more common in recent years, although
other classified prescription drugs are mentioned as well,
for instance various types of analgesics, sleeping pills,
and ADHD medication.
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methadone or buprenorphine
Outpatient clinics for young drug users is found in
Sweden’s three major cities—Stockholm, Gothenburg,
and Malmö—and in some smaller towns. The clinics are
open for adolescents and young adults through to the
age of 25. The target population is broadly defined and
encompasses everyone from 13 year-olds, who turn up
accompanied by a parent after their first brush with
alcohol or other drug experience, to young adults with a
more established drug problem. The majority of the
visitors, however, are not characterized by long-standing
or advanced drug use.
The clinics employ a new, joint documentation system,
UngDOK [27,31]. Between 2010 and 2012, a total of
2,003 visitors were registered at the outpatient clinics in
the three major cities. Cannabis was the most common
narcotic substance used by adolescents at some point
(86%), followed by amphetamine (14%), benzodiazepines
and cocaine (12% each), ecstasy (7%), methadone/
buprenorphine (2.2%), GHB (1.9%), and heroin (1.5%). A
substantial proportion of adolescents (19%) furthermore
claimed they had used some other drug, not specified on
the questionnaires, mainly in the form of various ‘designer
drugs’ (new synthetic drugs).
The great majority of adolescents/young adults stated
cannabis (64%) or alcohol (26%) as their main drug. Only
two people mentioned buprenorphine as their main drug,
and one person methadone.
Out of the 45 visitors (2.2%) who had used methadone/
buprenorphine, 32 had used buprenorphine only, seven
methadone only, while six had tried both methadone and
buprenorphine. The average age for methadone initiation
was 16.3 years, and 17.1 years for buprenorphine. A
small number of adolescents, however, made their debut
with one or the other of these substances before they had
turned 15. No one mentioned methadone or buprenorphine
as the first drug tried, and the majority had used a number
of other narcotic substances before trying methadone or
buprenorphine. On the other hand, a majority had used
methadone or buprenorphine before they tried heroin.
The great majority of those who at some point had
used methadone or buprenorphine, reported no use
within the last three months. Only three people had
used either of the substances extensively (two to three
days per week or more) within this period.
A number of representatives for the professions inter-
viewed encounter adolescents and young adults who are
using illegal drugs (see Table 1). These professionals
meet several thousand adolescents and young adults
every year.
On the whole, the interviewees outline similar obser-
vations. Cannabis is the dominant narcotic substance
among the young people they meet. Few of them haveused ‘hard drugs’, such as amphetamine, cocaine, or heroin.
That said, various synthetic substances and ‘designer drugs’
are also relatively frequent, and seems to be growing
increasingly common according to several informants.
The classified prescription drugs encountered are mainly
benzodiazepines, tramadol and codeine. Buprenorphine
and methadone, on the other hand, are not described by
anyone as common among the young people they come
into contact with, nor do they appear to have increased in
recent years. Those who have encountered young people
who have tried either of these two substances, say they are
limited to a few cases each year. Young people who try
methadone and buprenorphine have, according to the
informants, often tried a number of other drugs previously,
and have other drugs as their substance of choice. In the
words of a member of the treatment staff at an outpatient
clinic in Malmö:
For the adolescents and young adults who come to us,
cannabis is the most common problem by a long
stretch. Then comes tramadol, followed by
benzodiazepines. We very rarely come across young
people who have used methadone or buprenorphine.
As a result of the debate about diversion lately, we have
acquired a test strip for methadone, to be able to screen
for it. We have been screening for buprenorphine for a
long time. So far we’ve had no positive cases.
(Outpatient care unit for young people, Malmö)
In a few cases, professionals have encountered 14- to
16-year olds who have been buprenorphine or metha-
done positive, and a couple of interviewees describe how
young people have developed an addiction to either of
these substances. They describe cases where young
people have overdosed on methadone or buprenorphine,
and one informant told us of one teenager who died
following a methadone overdose. Such cases, however,
are rare exceptions.
Generally speaking, classified prescription drugs are
more prevalent than narcotic substances such as am-
phetamine, cocaine, and heroin among young drug
users. Several informants explain this phenomenon
by the fact that many prescription drugs are cheap
and easily accessible for adolescents, since they are
often to be found at home or in the homes of close
friends.
The rarity of buprenorphine and methadone compared
to other classified prescription drugs can be explained
by the fact that these substances are rarely found in the
immediate environment of young people, that most
young people are unaware of them, and that access to
substitution medication typically require contact with
OST-patients or other persons with an opiate or opioid
addiction.
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said, take any drug they can lay their hands on; those
who take tramadol and benzodiazepines probably
wouldn’t be averse to trying buprenorphine. However,
in order to get access to methadone and
buprenorphine you need to have to gone further
down the addiction road than most of our visitors
actually have. Most of our visitors don’t even know
what methadone or buprenorphine is when we bring
them up in our survey interviews. (Outpatient clinic
for young people in Malmö)
To summarize, also when it comes to adolescents and
young adults who are drug users, registry data and inter-
views with professionals paint a consistent picture:
methadone and buprenorphine use is highly unusual.
Adolescents and young adults with a severe drug
problem—many have tried methadone and
buprenorphine, few use them as their main drug of
choice
Information about young people with severe drug problems
is to be found in statistics from Statens institutionsstyrelse
(SiS, The National Board of Institutional Care), the Swedish
government agency that delivers compulsory care for young
people with psychosocial problems (the LVU-act) and for
adults with a life-threatening addiction (the LVM-act).
Since there are no data on the use of methadone and
buprenorphine, respectively, for those adolescents who are
taken into care under the LVU act, we have relied exclu-
sively on data about young adults who have been taken into
care under the LVM act.
Each year, some 1,000 adults are received into care at
LVM homes. Typically, the detainees have a history of
several years of drug addiction and in a majority of cases
detention at an LVM home is the result of immediate
action in a life-threatening situation (SiS 2012).
The statistics for the 18 to 29 age bracket for people in
LVM care in 2011 (n=290), indicate extensive and advanced
drug use: 93% had used cannabis, 86% amphetamine, 73%
ecstasy, 66% heroin, and 66% cocaine. Methadone had been
used by 54%, and other opiates/opioids by 66%. There is no
breakdown of the individual substances included in the lat-
ter category, nor any data of how many had used
buprenorphine. Of the methadone users, the overwhelming
majority (88%) had not undergone OST, a sign that the use
in most cases was illicit.
Data from the annual SiS report from the years
2002–2013 show a gradual increase in the proportion
of detainees having used methadone, from approx.
30% in 2002 to just over 50% in 2012. Over the last
10 years the average initiation age for methadone was
20–21 years, while the average initiation age for
heroin was 18–19 years. Of all narcotic substances,methadone was the one with the highest average initi-
ation age.
Our interviews with professionals who come across
young people with severe drug problems include police
officers in street dealer units, as well as staff at detoxifica-
tion units, treatment clinics for adults with an addiction,
and institutional and compulsory care homes for young
people (LVU homes) and adults (LVM homes).
According to our informants, illicit use of methadone
and/or buprenorphine is relatively common in this group.
The use of these substances appears to be especially
prevalent among adolescents and young adults who are
taken into compulsory care. However, methadone and
buprenorphine are not described as being among the most
commonly used substances by any of the professionals. In
this target population of drug users with more severe
problems, cannabis, amphetamine, and heroin dominate
as the primary drugs of choice. Classified prescription
drugs, such as tramadol and various benzodiazepines, also
feature more regularly than methadone and buprenorphine.
Those who have used methadone or buprenorphine are
mostly above the age of 20, and have a long history of drug
use, according to the informants, although they also point
to examples of younger people (15 to 17 years) who
have used the substances. The great majority, how-
ever, have previously used other opiates/opioids, and
are not using methadone or buprenorphine as their
main drug of choice.
Cannabis is the substance used by most, while
amphetamine, cocaine, and heroin are also common.
Various classified pills and prescription drugs are very
common, mainly benzodiazepines and tramadol, but
also buprenorphine. Probably more than half of the
young adults we receive here have used methadone or
buprenorphine illicitly, most often buprenorphine. Some
have used it while in substitution treatment as well, and
may have been thrown out, or be on the waiting list to
get admitted […] Prior to using methadone or
buprenorphine, most have used other opiates, typically
heroin or tramadol. (Staff member at compulsory care
home for adults with an addiction, Lund)
The professionals mainly point to two categories who
use methadone and buprenorphine illicitly. One category
consists of people with a heroin addiction, who periodic-
ally use methadone or buprenorphine because they are
unable to get hold of heroin, because they want to quit
heroin, or (as mentioned in the quote above) because
they are on the waiting list for, or have been excluded
from, OST. The second category consists of people
with an extensive polydrug use. This population uses
methadone or buprenorphine periodically, usually in
conjunction with alcohol or other substances.
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the most severe drug problems registry data and interviews
indicate a fairly uniform picture. Many members of this
population have used methadone and buprenorphine,
but very few have them as their main drugs of choice,
and, as a rule, these substances enter their drug careers at
a late stage.
Diversion and illicit use—the professionals’ view of the
phenomenon
Diversion and illicit use of methadone and buprenorphine
is not generally perceived as a widespread or serious
problem by the majority of the professionals interviewed.
For instance, this is what one of the drug squad officers
we interviewed had to say:
I consider the risk, at least considering the situation thus
far, of these substances spreading to younger people or
non-problem drug users as small […] Clearly there are
risks with these substances, that they will reach the
wrong people, but I don’t think it’s a big problem.
(Officer at the Street Dealer Unit of the Malmö Police)
Several professionals have expressed concerns over
what they see as a trend where adolescents increasingly
use various classified prescription drugs illicitly. This
trend, according to some informants, is associated with
an increase in the legal prescription of, and access to,
classified prescription drugs, and to a diminished respect
for such substances among young people.
Diversion and abuse of buprenorphine and
methadone is no more problematic than other
classified prescription drugs out there on the streets.
The big problem is that it’s easier for a young person
today to take a classified pill, and that threshold will
just get lower and lower. […] Tramadol,
benzodiazepines, and sleeping pills are probably pretty
common as gateways to drug abuse for young people
today. Many have access to potent prescription drugs at
home. There’s not much in the way of restrictions for a
number of these substances, not like for buprenorphine
or methadone. (RFHL, Riksförbundet för Rättigheter,
Frigörelse, Hälsa och Likabehandling—‘The National
Association for Rights, Freedom, Health, and
Equal Treatment’)
Operations working with drug seizures and/or drugs
testing (for instance, the police and the NGO ‘Parents
Against Drugs’) have not experienced any great change
in the accessibility of methadone and buprenorphine.
Only a few informants from treatment clinics describe
an increase in adolescent use of these substances in
recent years.The majority of informants from organizations working
in the addiction treatment field say that they are aware of
diversion from OST, and that there is an established black
market for these substances. A general view is that the
black market and the illicit use mainly concerns people
with a heroin or polydrug addiction. Some voice the
opinion that the black market primarily is structured
by the demand of people with an opiate/opioid addiction,
who either have not been admitted to OST, or have been
involuntarily discharged. Illicit use for such ‘self-medication’
purposes is seen by several informants as relatively
unproblematic, sometimes even as something positive.
Here is an example:
Of those we meet, more or less everyone who has
used methadone or buprenorphine has used heroin
previously. They are heroin users who, on their own,
are trying to cut down on the heroin or prefer
buprenorphine or methadone. […] I have met some
who save part of their dose and sell it on in order to
make some money. Clearly not a good thing, but that’s
the way it is. I sympathize with clients who are buying
their buprenorphine on the street to feel OK, instead of
running around, committing crimes in order to buy
heroin. It is, or at least it used to be, difficult to be
admitted into substitution treatment in Gothenburg.
(Addiction treatment clinic for adults, Gothenburg)
The risk of large-scale diversion of methadone or
buprenorphine to young drug users is generally seen as
low. Furthermore, the informants do not consider it
likely that these substances would work as a gateway to
other drugs. Their view is that young people do not have
access to methadone or buprenorphine to any particular
extent, nor that these substances are in any great
demand by them. A staff member at a compulsory care
institution explains:
I don’t think that illicit methadone or buprenorphine are
creating new drug user populations, no one starts with
these substances. They enter their [drug] careers quite
late, when the person already has a serious problem
with drugs. […] I believe other prescription drugs pose a
greater problem, for instance benzodiazepines and
tramadol. They are more easily accessible, cheap, and
enter the drug user’s life earlier in comparison to
buprenorphine, for example. (Staff member at
compulsory care home for adults with an addiction)
One risk, however, mentioned by representatives for
several professions, is that methadone and buprenorphine
may lead to fatal overdoses for people without opiate/
opioid tolerance. The substances are generally viewed
positively, as long as they are used by the right people for
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and dangerous if they end up in the wrong hands. ‘Illicit
use of methadone and buprenorphine may save lives as
well as take them,’ as one of the interviewees put it.
Discussion
Nothing in our results points to methadone or
buprenorphine being a major problem among young
drug users. The substances appear to be relatively
unknown, and very few adolescents and young adults have
tried them. Nor is there any evidence to suggest that
methadone or buprenorphine are serving as gateway drugs
for those who ultimately develop severe drug problems—a
claim often made in the Swedish debate.
The ‘gateway model’ is based on well-documented
statistical connections where the use of certain common
drugs (tobacco, alcohol, cannabis) precedes the use of
‘heavy drugs’, such as amphetamine, cocaine and heroin
[32-34]. Earlier and more frequent use constitutes an
increased risk for the young user to move on to heavier
drugs subsequently. Some researchers and scholars claim
that the links of the gateway model are based on causal
mechanisms of a biomedical or social nature, although
such views are not uncontroversial [35]. Methadone
and buprenorphine, however, cannot be considered as
gateway drugs in any respect. As substances they enter
drug careers at a late stage. In actual fact, methadone or
buprenorphine use tends to be a clear indication of a
person already having a severe drug problem, rather than
a risk factor for establishing such a problem.
There are various possible explanations as to why
methadone and buprenorphine are rare among adolescents.
Research into diversion and illicit use indicate that the
black market for these substances appears to be relatively
closed [18,36]. Methadone and buprenorphine are seldom
available from street dealers. Instead they are primarily sold
by patients in opioid substitution treatment, and the
customers mainly consists of persons with an opiate/opioid
or polydrug addiction. In comparison to other classified
prescription drugs, they are also strictly controlled. Our
study indicates that adolescents rarely have access to, or are
interested in, this market. A number of the professionals
interviewed also voice the opinion that most adolescent are
not even aware of these substances.
However, when it comes to adolescents and young adults
with severe drug problems, illicit use of methadone and
buprenorphine is far more common. In this population
there are persons who use these substances as their
main drug of choice, but in the majority of cases it is
rather a question of polydrug use where methadone and
buprenorphine are just two of many of substances.
One population of young drug users stand out in
particular—users with a heroin addiction. The great
majority of this population have used methadone orbuprenorphine. Previous research indicates that heroin
addicts mainly use methadone and buprenorphine for
self-medication purposes in order to avoid withdrawal
symptoms (‘to stay healthy’), to perform self-detoxification
or manage opioid substitution on their own [13,14,36].
Our study at least partly confirm these results, but the
knowledge of the situation of young people with severe
drug problems is still incomplete. Thus more research
is needed, for instance qualitative interview studies
investigating the users’ motives for using methadone
and buprenorphine, and their views on and knowledge of
the substances.
As mentioned in the introduction, diversion and illegal
use of methadone and buprenorphine is a cornerstone of
the criticism often leveled at opioid substitution treatment.
In Sweden, the debate has taken the form of an ideological
battle between opponents and representatives of this form
of treatment [37,38]. However, the voices of professionals
who regularly come into contact with young drug users
have not been heard.
Diversion and illicit use of methadone and buprenorphine
is, in general, not seen as a serious or growing problem by
the professionals interviewed. Nonetheless, some treatment
staff point out that for a small group of young people, the
substances may form part of a dangerous polydrug use, and
that they can cause fatalities among young people without
sufficient knowledge of or respect for these substances.
Accordingly, from a harm-reduction perspective, it is rea-
sonable to concentrate on interventions based on informing
young drug users about the risks of these substances.
Important target groups for such interventions are adoles-
cents and young adults in institutional and compulsory
care, as well as young drug users in outpatient treatment.
Measures to minimize diversion of methadone and
buprenorphine, and to target the illicit use of these
substances is an important issue. The design of such
measures, however, present difficult trade-offs, since
the advantages of offering easily accessible, effective,
and user-customized treatment for a large group of individ-
uals must be weighed against the negative effects of diver-
sion. The fact that the customers on the illicit market
mainly consist of opiate or opioid addicted individuals,
many of whom are using the substances for self-medication
purposes, needs to be taken into account in those
trade-offs.
Our results indicate that other classified prescription
drugs are used by adolescents to a far greater extent than
OST medication. Benzodiazepines and tramadol are exten-
sively prescribed to a broad user population, and are not as
strictly regulated as methadone and buprenorphine. More-
over, these prescription drugs enter the drug career of many
young users early, and appear to be relatively easily access-
ible. Research focusing on the illicit market of such sub-
stances is needed, as well as measures preventing illicit use.
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The illicit use of methadone and buprenorphine among
young drug users is not a widespread problem in Sweden.
Among adolescents and young adults with severe drug
problems, however, methadone and buprenorphine is
more common, and may cause dangerous health risks.
Harm-reduction measures, such as information about
overdose risks, should therefore target those groups. Pre-
scription drugs such as benzodiazepines and tramadol,
which are less controlled and more widely used among
young people, is of greater concern. Research focusing on
the illicit market for these substances, their possible role
in drug careers and their potential negative consequences
for users is needed.
Endnotes
aAfter many years with low treatment accessibility,
OST has increased substantially in Sweden during the
2000s. Today, there are over 5,000 OST-patients across
the country, a coverage rate of 50-75% (current estimates
of the number of people with an opiate/opioid addiction
are very uncertain). About half of the patients are pre-
scribed methadone, and the other half buprenorphine or
buprenorphine/naloxone. The main inclusion criteria for
OST are (1) age > 20 years and (2) a documented opiate
(heroin or morphine) addiction for at least one year.
According to government regulations, individuals with an
opioid addiction are not allowed to be admitted to OST.
Swedish OST is strictly controlled. During the first six
months, all patients are required to attend the clinic daily
for supervised medication. After that, control is gradually
reduced for compliant patients. Urine tests are taken
regularly. Patients who do not comply with treatment
regulations run the risk of being discharged, resulting
in a three-month “lockout” period.
bThe project includes an extensive quantitative inter-
view study with patients undergoing OST and injecting
opiate/opioid users, as well as a number of qualitative
in-depth studies and registry studies. The main themes
explored are (1) the extent of, and motives for diversion
from OST, (2) the patients’ views on various aspects
of their treatment, (3) the experiences of illicit use of
methadone and buprenorphine among various groups
of drug users, (4) methodological studies focusing on
the opportunities and risks of user involvement in re-
search, and (5) treatment staff views on, and management
of, diversion.
cIn Swedish schools, drugs tests are performed in
the event of suspected drug use. A few schools also
conduct random drugs tests even without reasonable
suspicion.
dMost of our informants use the medical product
name, Subutex, but in the quotes we have altered this to
the substance name throughout.Competing interests
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